Amol Akhade/hiranandanihospital.org
May 27, 2025, 17:55
Amol Akhade: DESTINY-Breast09 is One of ASCO 2025’s Most Anticipated Trials
Amol Akhade, Consultant Medical Oncologist at the Suyog Cancer Clinics, shared a post on LinkedIn:
“DESTINY-Breast09 is one of ASCO 2025’s most anticipated trials! Enhertu + Pertuzumab beat THP in 1L HER2+ MBC with a highly significant PFS benefit as per the press release. But the exact numbers aren’t out yet…
What do you think the results will show for the trial arm- Enhertu plus Pertuzumab – (HR + median PFS)? Think and give me your best guess: Vote now and opine on this survey on X.”
More posts featuring Amol Akhade.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
May 27, 2025, 17:55
May 27, 2025, 16:46
May 27, 2025, 16:43
May 27, 2025, 15:57
May 27, 2025, 15:48
May 27, 2025, 15:39
May 27, 2025, 14:17